Companies · Biotechnology

Regenerative Medical Solutions, Inc.

Madison · Biotechnology

Diligence memoA one-page analyst read on Regenerative Medical Solutions, Inc. — recommendation, valuation, rhythm, risks.
$7.0M
Total raised · real
5
Rounds
27.6×
Latest step-up
Top 51%
Sector rank · raised
Series A
Latest stage · inferred · Fri Aug 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Regenerative Medical Solutions, Inc. looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.89× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
  • Within the normal band (89% of peer median) for its niche.
At-risk
  • Last raise 2.9 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Regenerative Medical Solutions, Inc. is one of 4293 Biotechnology companies tracked from Madison. By capital raised it ranks mid-pack (ahead of 50% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2023-08-25
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2013-05-20 Raised $850K (real) Modeled valuation $47M (est)$850K$47MPre-Seed2013Pre-Seed · 2014-02-03 Raised $595K (real) Modeled valuation $33M (est)$595K$33MPre-Seed2014Pre-Seed · 2014-02-03 Raised $595K (real) Modeled valuation $33M (est)$595K$33MPre-Seed2014Pre-Seed · 2014-10-29 Raised $375K (real) Modeled valuation $21M (est)$375K$21MPre-Seed2014Pre-Seed · 2018-07-31 Raised $181K (real) Modeled valuation $10.0M (est)$181K$10.0MPre-Seed2018Series A · 2023-08-25 Raised $5.0M (real) Modeled valuation $40M (est)$5.0M$40MSeries A2023+$595K+$595K+$375K+$181K+$5.0MCumulative $7.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$850K · 2013
Pre-Seed extension$595K · 2014
Pre-Seed extension$595K · 2014
Pre-Seed extension$375K · 2014
Pre-Seed extension$181K · 2018
Series A$5.0M · 2023no Seed on file

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$39.6M
Base estimate est.
$5.5M
Conservative case
$104.2M
Upside case
$22.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $46.9M · 2013-05-202013Pre-Seed · modeled $32.8M · 2014-02-03Pre-Seed · modeled $32.8M · 2014-02-03Pre-Seed · modeled $20.7M · 2014-10-29Pre-Seed · modeled $10.0M · 2018-07-31Series A · modeled $39.6M · 2023-08-252023
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
2.9 yr
Elapsed time used
2.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
25 mo
Avg between rounds
$682K/yr
Capital velocity
13.1 yr
On record since
2013
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.0× of median
This company$7.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.9× of median
This company$5.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.6× of median
This company$39.6M
Sector median$64.2M

Raised more than 50% of sector peers (real $). Modeled value above 40% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #172 of 303.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $184.0M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)Regenerative Medical Solutions, Inc. (this company) Raised $7.0M · modeled $39.6M (est)Regenerative Medical Solutions, Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc.Series A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
Regenerative Medical Solutions, Inc. this companySeries A$7.0M$39.6M0.89×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$850K2013-05-20$4.7M$46.9M85%
Pre-Seed$595K2014-02-03$3.3M$32.8M85%
Pre-Seed$595K2014-02-03$3.3M$32.8M85%
Pre-Seed$375K2014-10-29$2.1M$20.7M85%
Pre-Seed$181K2018-07-31$1.0M$10.0M90%
Series A$5.0M2023-08-25$22.7M$39.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$850K2013-05-20
    • First recorded raise — entered as Pre-Seed.
    • 2 investors on this round.
  2. Pre-Seed$595K2014-02-03
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • Switched to Rule 506(c) (was Rule 06).
    • 9 investors on this round.
  3. Pre-Seed$595K2014-02-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(b) (was Rule 506(c)).
    • 9 investors on this round.
  4. Pre-Seed$375K2014-10-29
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  5. Pre-Seed$181K2018-07-31
    • Raised again after 45 mo — slower than the ~14 mo sector norm.
    • Round 2.1× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  6. Series A$5.0M2023-08-25
    • Raised again after 61 mo — slower than the ~14 mo sector norm.
    • Round 27.6× larger than the prior — scaling up.
    • 2 investors on this round.
Intelligence
2025 ~Q3
Modeled next raise · ~25mo cadence
$15.0M
Modeled next size est.range $9.8M$24.0M
27.6×
Last step-up
$682K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Anthony D. Kolton2013-05
Gary P. Gorman2014-02
Guy D. Tagliavia2014-02
Jon S. Odorico, MD, FACS2014-02
Thomas D. Joyce2014-10
Thomas P. Joyce2014-02
Registry & provenance

Regenerative Medical Solutions, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1579613
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Omnipulse Biosciences, Inc.BiotechnologySeries A$7.0M$47.8Msame sector · same stage
OptoVista Holdings, LLCBiotechnologySeries A$7.0M$34.3Msame sector · same stage
Amplifyer Bio, Inc.BiotechnologySeries A$7.1M$33.1Msame sector · same stage
Clear Creek Bio, Inc.BiotechnologySeries A$7.1M$37.1Msame sector · same stage
Catheter Connections, Inc.BiotechnologySeries A$6.8M$38.9Msame sector · same stage
Holobiome, Inc.BiotechnologySeries A$7.5M$40.0Msame sector · same stage
Stemina Biomarker Discovery, Inc.BiotechnologySeries A$7.9M$36.2Msame sector · same stage
Anelixis Therapeutics, Inc.BiotechnologySeries A$7.9M$36.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
RegenX Science Inc.BiotechnologySeries A$62.4M89%
Regenimo Biosciences, Inc.BiotechnologySeed$4.6M89%
BioRestorative Therapies, Inc.BiotechnologySeries A$4.0M89%
Regenerx Biopharmaceuticals IncPharmaceuticalsSeries A$40.3M88%
Recros Medica, Inc.BiotechnologySeries A$149.0M88%
Reglagene, Inc.BiotechnologySeries A$4.3M88%
Reprogram Biosciences, Inc.BiotechnologyPre-Seed$2.7M88%
Medical Nutrition Innovation, Inc.BiotechnologySeed$55.5M88%
Frequently asked
How much funding has Regenerative Medical Solutions, Inc. raised?
Regenerative Medical Solutions, Inc. has raised approximately $7.0M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Regenerative Medical Solutions, Inc.'s estimated valuation?
Provath's modeled valuation for Regenerative Medical Solutions, Inc. is approximately $39.6M (modeled range $5.5M–$104.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Regenerative Medical Solutions, Inc. at?
Regenerative Medical Solutions, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Aug 25.
What does Regenerative Medical Solutions, Inc. do and where is it based?
Regenerative Medical Solutions, Inc. operates in the Biotechnology sector, based in Madison.
Explore related

See where Regenerative Medical Solutions, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Regenerative Medical Solutions, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.